One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial

By sjmartinez • June 7, 2023

Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023 Jun 5:ciad342. doi: 10.1093/cid/ciad342. Epub ahead of print. PMID: 37279602.

Tags: camostat, covid-19, Infectious Diseases, outpatient, phase 2, Publications, SARS-CoV-2

West Nile Morbidity and Mortality in a Mid-Atlantic Health Care System, 2013-2024

Judson SD, Auwaerter P, Dowdy D. West Nile Morbidity and Mortality in a Mid-Atlantic Health Care System, 2013-2024. Am J Trop Med Hyg. 2026 Apr[...]

Church-based problem-solving therapy for adolescent girls and young women with a history of gender-based violence in Zambia: study protocol for a hybrid type 1 randomized controlled trial

Ahmed CV, Thornicroft M, Chileshe K, Ntebeka BM, Dovel K, Bogart LM, Chávez NR, Bwalya FT, Brooks MJ, Swendeman D. Church-based problem-solving therapy for adolescent[...]

Integrin ß4 is a receptor for emerging fungal pathogens from the genera Lomentospora and Scedosporium

Kavaliauskas P, Risteen R, Alkhazraji S, Shirtliff B, Walsh TJ, Ibrahim AS, Bruno VM. Integrin ß4 is a receptor for emerging fungal pathogens from the[...]